Public release date: 23-Aug-2013 [ | E-mail | Share ]

Contact: Vicki Cohn vcohn@liebertpub.com 914-740-2100 Mary Ann Liebert, Inc./Genetic Engineering News

New Rochelle, NY -- With the widespread popularity of social networking sites such as Facebook, it is increasingly common for people to use interpersonal electronic surveillance to monitor the activities of current and former romantic partners. They can gather information on partners anonymously, view past and current photos and audio and video clips, and look for clues to explain any "suspicious" behaviors. Why some individuals engage in this type of behavior more than others is the subject of an article in Cyberpsychology, Behavior, and Social Networking, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the Cyberpsychology, Behavior, and Social Networking website.

The article "Social Networking Sites in Romantic Relationships: Attachment, Uncertainty, and Partner Surveillance on Facebook," describes a study to determine what individual characteristics might be predictive of using electronic surveillance to gather information about a romantic partner. Authors Jesse Fox, PhD, Ohio State University, Columbus, and Katie Warber, PhD, Wittenberg University, Springfield, OH, explored several variables including a partner's attachment style, the role of sex, and a partner's level of relationship anxiety, which is likely to be higher among more preoccupied and fearful individuals.

"Prior to social networking tools, it was more difficult to monitor a former partner's life," says Brenda K. Wiederhold, PhD, MBA, BCIA, Editor-in-Chief of Cyberpsychology, Behavior, and Social Networking, from the Interactive Media Institute, San Diego, CA. "While social networking provides many positives, the ability to conduct interpersonal electronic surveillance may lead some individuals to suffer with prolonged feelings of uncertainty after a relationship ends. These results presented here should, however, be interpreted with caution, since the sample was comprised of heterosexual college students and may not extend to other groups."

###

About the Journal

Cyberpsychology, Behavior, and Social Networking is a peer-reviewed journal published monthly online with Open Access options and in print that explores the psychological and social issues surrounding the Internet and interactive technologies, plus cybertherapy and rehabilitation. Complete tables of content and a sample issue may be viewed on the Cyberpsychology, Behavior, and Social Networking website.

About the Publisher

Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Games for Health Journal, Telemedicine and e-Health, and Journal of Child and Adolescent Psychopharmacology. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's over 70 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.

Continued here:
Who uses social networking sites to monitor their romantic partners?

Recommendation and review posted by Bethany Smith

Despite the fact that only 27 percent of people said they knew what personalized medicine is (and only 4 percent could describe it accurately) , more than 50 percent of consumers are aware of genetic tests and keen to have them. It indicates that a growing number of people may be interested in testing before they get sick.

A survey by market research firm GfK found that the more health concerns participants had, the more interested they were in genetic tests and personalized medicines potential. For example, of the 602 people who participated in the online survey, just over 14 percent said they were very interested in genetic tests but that figure jumped to 48 percent if the respondent had cancer. Cost associated with testing was the biggest concern for 45 percent of respondents.

The majority, 65 percent, preferred to hear about genetic tests through their physician or nurse rather than the Web (45 percent) or mailings to their house accompanies by educational material (31 percent).

But personalized medicine remains more of a curiosity beyond industry publications and those who have a personal stake in knowing about it i.e., patents. It will take longer before it becomes more widely understood to the general public.

Go here to read the rest:
Personalized medicine needs 23andMe awareness campaign

Recommendation and review posted by Bethany Smith

By Jim Dryden - Part of the risk for alcohol dependence is genetic, and the same is true for eating disorders. Now, researchers at Washington University School of Medicine in St. Louis have found its likely some of the same genes are involved in both.

In clinical practice, its been observed that individuals with eating disorders also have high rates of alcohol abuse and dependence, said Melissa A. Munn-Chernoff, PhD, the studys first author. Other studies have focused on the genetic connections between alcohol dependence and eating disorders, but all of those studies looked only at women. Ours was the first to include men as well.

According to Munn-Chernoff, a postdoctoral research scholar in psychiatry, thats important because although eating disorders tend to be thought of as a female problem, they affect men, too.

By studying twins, the researchers used statistical methods to determine the odds that certain traits result from the same genes. Those statistical insights are based on the fact that identical twins share 100 percent of their genetic makeup while fraternal twins share about half.

By comparing the findings in identical and fraternal twins, we can develop estimates of how much of the difference in particular traits is due to genes or environment, Munn-Chernoff explained. We found that some of the genes that influence alcohol dependence also influence binge eating in men and women.

Even with the growing awareness and more frequent diagnoses of problems such as anorexia nervosa and bulimia nervosa, rates of the full-blown forms of these disorders are relatively low, and theyre rare in populations of twins. So the researchers surveyed study subjects about whether they suffered from eating-disorder symptoms.

The symptoms can cut across multiple eating disorder diagnoses, said Munn-Chernoff. And several past studies have suggested that the particular behavior of binge eating, as well as purging and other practices that we call compensatory behaviors, may be closely associated with alcohol dependence, which is why we focused on those symptoms.

All of the men and women in the study were surveyed about their alcohol use and binge eating, but because the researchers were analyzing data that had been gathered previously for a different study, not everyone was asked about compensatory behaviors, such as purging or using laxatives and diuretics. Only the female twins were asked about those symptoms.

In all, nearly 25 percent of the men and 6 percent of women had been alcohol dependent at some point. Almost 11 percent of these same men and 13 percent of the women had experienced problems with binge eating. In addition, about 14 percent of the women had engaged in purging or abuse of laxatives or diuretics.

On a statistical scale that runs from zero (no shared genes) to 1 (all genes shared), the researchers found that the genetic correlation between binge eating and alcohol dependence was statistically significant at .26.

Go here to see the original:
Genetic Link Between Alcohol Abuse and Eating Disorders

Recommendation and review posted by Bethany Smith

12 hours ago Aug. 23, 2013 - 7:23 AM PDT

Plenty of genetic testing and analysis startups want to use personalized medicine to revolutionize healthcare but theres one thing they may have to do first: help consumers understand what that actually means.

According to a report released this week from research firm GfK, just 27 percent of U.S. consumers said theyd heard of the term personalized medicine, and just 4 percent could accurately describe it as medical care that matched a persons genetic makeup.

Once respondents were told what it meant, the study, which included more than 600 people in the general population over the age of 30, found that 55 percent of people with work-sponsored health plans said they were interested in having a genetic test. Not surprisingly, that figure rose to 80 percent among those who have or have had cancer and, in general, interest increased among those who have more medical conditions.

With the approach of the more-affordable so-called $1,000 genome, the phrase personalized medicine has become more ubiquitous. Several companies, from genetic testing firms 23andme and Gene by Gene to genomic data processing and analysis startups Bina Technologies and Spiral Genetics, are working on technology to help doctors provide care thats most appropriate for a persons genetic characteristics.

That could mean using genetic assessments to determine whether a patient is a slow processor of caffeine or whether theyre at a higher risk for diabetes and other inherited conditions and then recommending the most fitting healthcare regime, or discovering which drugs are most incompatible with a persons genetic predispositions.

Its true that patients dont need to know the term personalized medicine to benefit from genetic testing and consumer-facing companies like 23andme tend to market with plainer language that more generally explains how DNA tests [are] improving lives. But the study still points out that these companies have a bit of work cut out for them when it comes to consumer education.

Subscriber Content

Subscriber Content comes from GigaOM Pro, a revolutionary approach to market research without the high price tag. Visit any of our reports to subscribe.

View original post here:
Pop quiz: do you know what personalized medicine means?

Recommendation and review posted by Bethany Smith

Genetics Softball 2013 Game Clips 081813
Team Genetics Softball Video Clips from the 2013 Season.

By: softballcoordinator

See the rest here:
Genetics Softball 2013 Game Clips 081813 - Video

Recommendation and review posted by Bethany Smith

Brown vs Dun (Pigeon genetics)
Listed below is a series of Pigeon standards describing brown, dun and khaki. (click #39;Show more #39;) Yes these are different breeds but it is all the same color...

By: FlyingTipplers

See the article here:
Brown vs Dun (Pigeon genetics) - Video

Recommendation and review posted by Bethany Smith

Perfect Genetics challenge pt2 Someone #39;s pregnant
In this part we found out that Lily is pregnant. Aslo we see what Fellipe #39;s dreams are about. Sims 3 page: http://mypage.thesims3.com/mypage/sharlize23 Twitt...

By: Simmerlover3

More:
Perfect Genetics challenge pt2 Someone's pregnant - Video

Recommendation and review posted by Bethany Smith

Whtie and yellow Genetics on display

By: LuxuriousLeopards

More:
Whtie and yellow Genetics on display - Video

Recommendation and review posted by Bethany Smith

Population Regulomics: Applying Population Genetics to the Cis-Regulome - Troy Ruths
View more information on the DOE CSGF Program at http://www.krellinst.org/csgf.

By: Krell Institute

See more here:
Population Regulomics: Applying Population Genetics to the Cis-Regulome - Troy Ruths - Video

Recommendation and review posted by Bethany Smith

Monica Coenraads Interviews Gail Mandel, Ph.D. and Lab Members
On August 21, 2013 the Journal of Neuroscience published a paper from the Mandel lab suggesting that gene therapy reverses symptoms in fully symptomatic mice...

By: reverserett

More:
Monica Coenraads Interviews Gail Mandel, Ph.D. and Lab Members - Video

Recommendation and review posted by Bethany Smith

Will Gene Therapy Cure Cancer? | Fw:Thinking
Gene therapy, an alteration of genes within the body to fight or prevent disease, has sparked a revolution in cancer treatment. Cancer is the 2nd leading cau...

By: fwthinking

Read more here:
Will Gene Therapy Cure Cancer? | Fw:Thinking - Video

Recommendation and review posted by Bethany Smith

Scientists have come a step closer to being able to repair the damage done by heart attacks, using a cocktail of genes to transform scar tissue into working heart muscles.

Novel techniques to mend broken hearts using gene therapy and stem cells represent a major new frontier in the treatment of heart disease.

In the latest breakthrough, achieved by researchers at the Gladstone Institute of Cardiovascular Disease in California, researchers were able to re-programme scar-forming cells into heart muscle cells, some of which were capable of transmitting the kind of electrical signals that make the heart beat, according to the latest issue of the Stem Cell Reports journal.

The same team demonstrated their technique last year in live mice, transforming scar-forming cells, called fibroblasts, into beating heart muscle cells, but this is the first time that human fibroblasts have been re-programmed in this way.

So far, the work with human fibroblasts has only been done in the lab, but it paves the way for new treatments for heart attack victims. Researchers said that the cocktail of genes used to regenerate cells could one day be replaced with small drug-like molecules that would offer safer and easier delivery.

We've now laid a solid foundation for developing a way to reverse the damage [done by a heart attack] something previously thought impossible and changing the way that doctors may treat heart attacks in the future, said Dr Deepak Srivastava, director of cardiovascular disease at the Gladstone Institutes. Our findings here serve as a proof of concept that human fibroblasts can be re-programmed successfully into beating heart cells.

In 2012, Dr Srivastava and his team reported in the journal Nature that, by injecting three genes into the hearts of live mice that had been damaged by heart attack, fibroblasts could be turned into working heart cells.

The scientists attempted the same technique using human fibroblasts from foetal heart cells, embryonic stem cells and neonatal skin cells, injected with genes in petri dishes in the lab. An increased number of genes was required to transform the human cells, and the efficiency of the transformed cells was low, but the team were encouraged by the results.

While almost all the cells in our study exhibited at least a partial transformation, about 20 per cent of them were capable of transmitting electrical signals a key feature of beating hearts, said Gladstone staff scientist Ji-dong Fu, the studys lead author.

The number of people who survive heart attacks has increased considerably in recent decades. The British Heart Foundation (BHF) said earlier this year that 70 per cent of women and 68 per cent of men were now surviving. However, success in keeping people alive after a heart attack has led to a rise in the number of people suffering from the long-term after-effects, which include debilitating heart failure.

Continued here:
Scientists use gene therapy to repair muscles damaged in heart attacks

Recommendation and review posted by Bethany Smith

Personalized Medicine in the BioRN Cluster

By: TheBioRNcluster

Read the original post:
Personalized Medicine in the BioRN Cluster - Video

Recommendation and review posted by sam

WALNUT CREEK, Calif., Aug. 21, 2013 /PRNewswire/ -- The little known FMR1 gene was first mapped in 1991. It was originally thought to cause only fragile X syndrome (FXS) when the gene mutates, but scientists have since discovered that the same mutation that causes the developmental and intellectual disabilities associated with FXS can also cause impaired female fertility (fragile X-associated premature ovarian insufficiency or FXPOI) and a progressively debilitating neurodegenerative disorder that resembles a daunting combination of Alzheimer's and Parkinson's diseases known as fragile X-associated tremor/ataxia syndrome (FXTAS). Together these three are now referred to as Fragile X-Associated Disorders (FXDs).

That's a lot for a single gene to be responsible for, but the FMR1 gene's long-suspected connection to autism has become much clearer within the last 18 months. Recent research has confirmed that there are likely hundreds of genes that can mutate spontaneously or in combination with environmental factors to cause autism. What many refer to as an autism "epidemic" has been slow to give up its secrets, but the identification of hundreds of autism-causing gene candidates is truly a giant step along the road to battling the condition.

What's more, it now appears that the little FMR1 gene also plays what may turn out to be a significant role in autism. As many as half of the suspect autism genes are now known to be regulated (controlled) by the FMR1 gene. This should really come as no surprise since various studies have found that up to 60 percent or more of individuals living with FXS also exhibit enough symptoms of autism to place them squarely on the autism spectrum. Many in the field are convinced that the molecular connection between the Fragile X gene and its protein and autism is among the best and most solid leads to figure out what causes autism.

Yet another recent study documents (for the first time) a subset of individuals with autism who, while they do not have a mutation in their FMR1 gene, do have an abnormally low level of FMRP (the protein made by the FMR1 gene).

These significant findings have not been lost on the major drug companies. At least three such companies are in various stages of human clinical trials of experimental drugs to reverse core symptoms that are shared between FXS and autism. A drug that could be approved for a population as large as those diagnosed with autism has gotten a lot of people's attention, and those in Fragile X research are thrilled to have discovered what some are already calling the key to unlocking autism. While a simplification of a complex process, their thinking is clear: the symptoms of FXS and autism may be caused by the same mechanism in the brain, and a drug capable of reversing that could effectively treat (or dare we say, reverse) both conditions.

As if that weren't enough importance for what's now looking like an "uber" gene for brain development and function, an international team of researchers from the Wellcome Trust Sanger Institute, the Broad Institute of MIT and Harvard, and the Institute for Molecular Medicine Finland have added schizophrenia to the growing list of conditions in which the FMR1 gene might play a role. In studies published just this week, the authors document a mutation in a protein believed to play a role in causing schizophrenia and, like autism researchers before them, have linked this protein to the Fragile X gene and its FMR1 protein.

According to the study's co-author, Dr. Nelson Freimer, a professor of psychiatry at UCLA, the experiments showed that the suspected schizophrenia-causing protein interacts with FMRP. That's the same FMRP, the loss of which causes fragile X syndrome, is the leading cause of inherited forms of autism, and is the most common cause of developmental disability among boys.

"These two disorders, schizophrenia and fragile X syndrome, although they may seem drastically different, share key features, particularly the cognitive impairment that is frequently associated with both conditions," said Freimer for an article on the website PsychCentral.com. "So, it is not unexpected that they could share some of the same biological processes."

A second study from the U.S. National Institutes of Health, also published this week in Nature Neuroscience, outlined an identical relationship between schizophrenia and Fragile X.

Although relegated to relative obscurity for many years, we're likely to start seeing a lot more in the scientific and popular media about the FMR1 gene, its FMRP protein and fragile X syndrome. Increased government funding of these exciting connections is sure to follow.

Read the original here:
All Genes Are Not Created Equal

Recommendation and review posted by Bethany Smith

Public release date: 22-Aug-2013 [ | E-mail | Share ]

Contact: Vicki Cohn vcohn@liebertpub.com 914-740-2100 Mary Ann Liebert, Inc./Genetic Engineering News

New Rochelle, NY, August 22, 2013Risk factor modification efforts could help reduce the chance of another heart attack and death among the more than 15 million Americans with coronary heart disease. Yet some patientsespecially women and minoritiesleave the hospital with poorly managed risk factors. An article in Journal of Women's Health, a peer-reviewed publication from Mary Ann Liebert, Inc., publishers, evaluates cardiac risk factors and management strategies by age, sex, and race among 2,369 patients hospitalized for acute myocardial infarction. The article is available free on the Journal of Women's Health website at http://www.liebertpub.com/jwh.

About 93% of the patients in the study had at least one of the five cardiac risk factors evaluated, including hypertension, hypercholesterolemia, current smoking, diabetes, and obesity. Black patients were much more likely to have multiple risk factors than white patients, and black women had the greatest risk factor burden of any of the subgroups. Differences in risk factor modification efforts based on race were also reported.

Erica Leifheit-Limson, PhD and coauthors from Yale School of Public Health and School of Medicine, and Yale-New Haven Hospital (New Haven, CT), St. Luke's Mid America Heart Institute and University of Missouri-Kansas City (Kansas City, MO), and Emory University Rollins School of Public Health and the School of Medicine (Atlanta, GA) report the study results in the article "Prevalence of Traditional Cardiac Risk Factors and Secondary Prevention Among Patients Hospitalized for Acute Myocardial Infarction (AMI): Variation by Age, Sex, and Race."

"These findings indicate missed opportunities for both prevention and management of cardiac risk factors, particularly for women and minority patients," says Susan G. Kornstein, MD, Editor-in-Chief of Journal of Women's Health, Executive Director of the Virginia Commonwealth University Institute for Women's Health, Richmond, VA, and President of the Academy of Women's Health.

###

About the Journal

Journal of Women's Health, published monthly, is a core multidisciplinary journal dedicated to the diseases and conditions that hold greater risk for or are more prevalent among women, as well as diseases that present differently in women. The Journal covers the latest advances and clinical applications of new diagnostic procedures and therapeutic protocols for the prevention and management of women's healthcare issues. Complete tables of content and a sample issue may be viewed on the Journal of Women's Health website at http://www.liebertpub.com/jwh. Journal of Women's Health is the Official Journal of the Academy of Women's Health and the Society for Women's Health Research.

About the Academy

Original post:
Risk factor reduction after heart attack -- age, race, and gender matter

Recommendation and review posted by Bethany Smith

NEW YORK--(BUSINESS WIRE)--

If personalized treatments are poised to change the face of medicine, that may be news to almost three-quarters of US consumers. In a 2013 study by GfK Bridgehead, a division of GfKs Health team, only 27% of respondents said they had heard of the term personalized medicine, and just 8% considered themselves very knowledgeable about the concept.

More than half (53%) said that personalized medicine refers to medical care somehow geared to individual needs, while others thought the phrase had something to do with doctor/patient collaboration. Just 4% associated personalized medicine with genetics, which is generally considered a key element.

To download a free report about this study, click here.

After being given more information about personalized medicine, consumers varied widely in their receptivity, as well as their openness to genetic testing. Those who perceived their health as poor were less likely to embrace personalized medicine; but people diagnosed with life-threatening cancer were more open to genetic testing, perhaps because of their own experiences with the imperfections of the current system.

The study showed that respondents who are more interested in genetic testing are likely to have

Over half (55%) of those with a work-sponsored health plan said they were interested in having a genetic test a figure that rose to 65% when they learned that a hypothetical test cost $500. With more and more individuals responsible for paying for portions of their care, patients receptivity to costs for different care approaches is an important area to understand.

In addition, respondents who had been diagnosed with life-threatening cancer were twice as likely to express a significant interest in genetic testing, compared to the general population (67% versus 32%).

Without strong consumer awareness, personalized medicine will have a hard time winning acceptance and delivering its promised benefits, said Susan Garfield, Senior Vice President of GfK Bridgehead. Our study points to specific communities that are more likely to be unaware or cautious when it comes to personalized therapies and genetic testing. As such, payers, clinicians, and other stakeholders need to work together to educate all patients about the potential benefits of this new approach to care. Educational efforts need to take into account the different perspectives patients bring into that conversation; not all will immediately see the benefits. Such initiatives need to meet people where they are.

The study also showed that 87% of respondents expected personalized medicine would increase healthcare costs either significantly or moderately over the next five years. Only a very small group of people said they were generally interested in predicting what diseases they might get in the future; but, when asked about specific life-threatening illnesses such as Alzheimers disease and diabetes 70% to 80% said they would want to know if they were at risk.

Link:
Only 27% of US Consumers Have Heard of “Personalized Medicine”

Recommendation and review posted by Bethany Smith

dEAD mAN gENETICS CLEARING OUT COMPUTER 3
dEAD mAN gENETICS CLEARING OUT COMPUTER 3 *** SUBSCRIBE TO GET UPDATES ON LOCAL EVENTS COVERED BY UGS PRODUCTIONS*** DJ FARROUT UGS PRODUCTIONS FILMED BY D...

By: djfarrout

More here:
dEAD mAN gENETICS CLEARING OUT COMPUTER 3 - Video

Recommendation and review posted by Bethany Smith

dEAD mAN gENETICS CLEARING OUT COMPUTER 4
dEAD mAN gENETICS CLEARING OUT COMPUTER 4 *** SUBSCRIBE TO GET UPDATES ON LOCAL EVENTS COVERED BY UGS PRODUCTIONS*** DJ FARROUT UGS PRODUCTIONS FILMED BY D...

By: djfarrout

Follow this link:
dEAD mAN gENETICS CLEARING OUT COMPUTER 4 - Video

Recommendation and review posted by Bethany Smith

Inspirational transformation (zyzz genetics)
#1063; #1091; #1074; #1072; #1082; #1074; #1076; #1086; #1093; #1085; #1086; #1074; #1080; #1083; #1089; #1103;, #1080; #1088; #1077; #1096; #1080; #1083; #1089; #1090; #1072; #1090; #1100; #1082; #1072; #1082; Zyzz. Dude was inspired and decided to become like Zyzz. Comment))))

By: #1052; #1072; #1075; #1086; #1084; #1077; #1076; #1052; #1091; #1089; #1091; #1083; #1100; #1084; #1072; #1085; #1080; #1085;

Originally posted here:
Inspirational transformation (zyzz genetics) - Video

Recommendation and review posted by Bethany Smith

GENETICS could be used to decrease methane emissions from cattle.

Early results from research by the NSW Department of Primary Industries has shown the potential to select for cattle with lower methane emissions.

The work, carried out at the University of New England campus at Armidale, has been the biggest test of its kind.

And it has prompted key researcher Kath Donoghue to speculate there could be estimated breeding values for methane within a few years.

Dr Donoghue said it was possible to select stock with lower emissions. Early results had shown this may not mean the selection of lower-performing animals.

"Early results are showing there is no antagonistic relationship between methane and growth and body composition," she said.

"We need a better understanding of the relationship with the profitability traits.

"But it could be that down the track there is a dollar index for environmentally friendly production. That could be that you buy a bull that is regarded as a low methane animal, and it will breed for low methane progeny."

Dr Donoghue said it could also mean producers may be able to apply for carbon credits.

"Cattle and sheep emit methane, a potent greenhouse gas, but there are few technologies available to mitigate methane emissions in extensive beef production systems," she said.

More:
Genetics may cut methane

Recommendation and review posted by Bethany Smith

SEATTLE, WA--(Marketwired - Aug 22, 2013) - Atossa Genetics, Inc. (NASDAQ: ATOS), the Breast Health Company, will visit the NASDAQ MarketSite in Times Square to celebrate its listing on the NASDAQ Stock Market, which occurred on November 8, 2012. In honor of the occasion, Dr. Steven C. Quay, Chairman, President and Chief Executive Officer, will ring the closing Bell.

Where:NASDAQ MarketSite -- 4 Times Square -- 43rd & Broadway -- Broadcast Studio When:Monday, August 26nd, 2013 -- 3:45 pm to 4:00 pm ET How:A live webcast of the NASDAQ Closing Bell will be available at: http://www.nasdaq.com/about/marketsitetowervideo.asx

Dr. Steven C. Quay, Chairman, CEO and President, stated, "As a leading molecular diagnostics company, we offer unique innovative solutions for breast health, including our ForeCYTE Breast Health Test, an early warning system for precancerous abnormalities that may lead to breast cancer. We are pleased to have a listing on NASDAQ as it provides an efficient platform to grow our business."

Dr. Quay continued, "We look forward to an exciting event at Nasdaq for friends and family of Atossa Genetics, including Ms. Sidney Powell, founder of Sidney Powell, P.C., a law firm dedicated to federal appellate practice, and Mr. Steven Bernstein, Director of the soon-to-be-released feature film Decoding Annie Parker, which tells the story of Annie Parker, a breast cancer victim."

About the ForeCYTE Breast Health Test

The ForeCYTE Breast Health Test, intended for the 110 million women in the U.S. ages 18 to 73, is a painless, quick and non-invasive procedure that can be done in a physician's office. A small sample of fluid, aspirated from the nipple of each breast with the Company's modified breast pump, can provide vital early detection of cancer or pre-cancerous conditions that may progress to cancer over an approximately eight year period and before cancer can be detected by mammography or other means and without the risks of radiation, especially in women younger than age 50. No invasive biopsy needles or open surgical incisions are used in the Atossa test and the test is painless.

Just as the Pap smear has reduced cervical cancer rates by over 70 percent, becoming the most successful screening test in medicine, the goal of Atossa Genetics is to reduce the stubbornly high rate of breast cancer through the early detection of the precursor changes that can lead to breast cancer and the treatment of those early changes.

About Atossa Genetics, Inc.

Atossa Genetics, Inc. (NASDAQ: ATOS), The Breast Health Company, based in Seattle, WA, is focused on preventing breast cancer through the commercialization of patented, FDA-designated Class II diagnostic medical devices and, through its wholly-owned subsidiary, the National Reference Laboratory for Breast Health, Inc. (NRLBH), patented, laboratory developed tests (LDT) that can detect precursors to breast cancer up to eight years before mammography.

The NRLBH is a CLIA-certified high-complexity molecular diagnostic laboratory located in Seattle, Washington.

View original post here:
Atossa Genetics to Ring the NASDAQ Stock Market Closing Bell in Celebration of Recent Listing on NASDAQ Stock Market

Recommendation and review posted by Bethany Smith

SEATTLE, WA--(Marketwired - Aug 22, 2013) - In the news release, "Atossa Genetics and Its Subsidiary the National Reference Laboratory for Breast Health to Exhibit Their Products and Services at Two Upcoming Conferences," issued Wednesday, August 21, 2013 by Atossa Genetics, Inc. (NASDAQ: ATOS), we are advised by the company that the second embedded link of the first paragraph should go to "http://www.survivorsconvention.com/" rather than "http://gaobgyn.com/resources/meeting-events/" as originally issued. Complete corrected text follows.

Atossa Genetics and Its Subsidiary the National Reference Laboratory for Breast Health to Exhibit Their Products and Services at Two Upcoming Conferences

SEATTLE, WA -- August 21, 2013 --Atossa Genetics Inc. (NASDAQ: ATOS) and its subsidiary The National Reference Laboratory for Breast Health (NRLBH), will display their products and services at the Georgia Obstetrical and Gynecological Society 2013 Annual Meeting, August 22-25, in Greensboro, Georgia, and at the inaugural National Women's Survivors Convention, August 22-24, in Nashville, Tennessee.

The ForeCYTE Breast Health Test, provided by the NRLBH, detects reversible precancerous conditions in the breast up to eight years before they become cancer. The test uses a sample of nipple aspirate fluid collected with Atossa's hand-held, FDA Class II medical device which is quick, painless, and non-invasive and can be administered during an OB/GYN office visit. Unlike mammograms, which are commonly recommended for women starting at age 40 to 50, the ForeCYTE Breast Health Test is more age agnostic, uses no radiation and does not require invasive biopsy needles or surgical incisions. To view a video about Atossa's device, click here: https://vimeo.com/62365818.

"The ForeCYTE Breast Health Test serves as an early warning system for the detection of precancerous cellular abnormalities that heighten a woman's breast cancer risk," said Chris Destro, Vice President of Sales and Marketing. "This is particularly true for younger women for whom little is done today in terms of risk assessment or screening unless there is a specific reason for concern, such as a strong family history. We believe the ForeCYTE Breast Health Test empowers all women with vital information that they and their doctors can use to take charge of their breast health and make more informed treatment decisions."

Mr. Destro continued, "We are excited to work with outstanding organizations like the Women Survivors Alliance, which provide vital services to breast cancer victims. In times of trouble women need to come together, share information and feel the support of other women as they cope with their disease and their new normal. As we continue to roll out the ForeCYTE test nationally, we believe we will have a significant impact on the incidence of this dreaded disease so that in the future fewer women will be afflicted. We look forward to meeting with physicians, patients and other breast health stakeholders at these important conferences."

Atossa's specimen collection devices are available through physicians nationwide.

About Atossa Genetics, Inc.

Atossa Genetics, Inc. (NASDAQ: ATOS), The Breast Health Company, based in Seattle, WA, is focused on preventing breast cancer through the commercialization of patented, FDA-designated Class II diagnostic medical devices and, through its wholly-owned subsidiary, the NRLBH, patented, laboratory developed tests (LDT) that can detect precursors to breast cancer up to eight years before mammography.

The NRLBH is a CLIA-certified high-complexity molecular diagnostic laboratory located in Seattle, Washington.

See the original post:
/ CORRECTION - Atossa Genetics, Inc.

Recommendation and review posted by Bethany Smith

Scientists have come a step closer to being able to repair the damage done by heart attacks, using a cocktail of genes to transform scar tissue into working heart muscles.

Novel techniques to mend broken hearts using gene therapy and stem cells represent a major new frontier in the treatment of heart disease.

In the latest breakthrough, achieved by researchers at the Gladstone Institute of Cardiovascular Disease in California, researchers were able to re-programme scar-forming cells into heart muscle cells, some of which were capable of transmitting the kind of electrical signals that make the heart beat, according to the latest issue of the Stem Cell Reports journal.

The same team demonstrated their technique last year in live mice, transforming scar-forming cells, called fibroblasts, into beating heart muscle cells, but this is the first time that human fibroblasts have been re-programmed in this way.

So far, the work with human fibroblasts has only been done in the lab, but it paves the way for new treatments for heart attack victims. Researchers said that the cocktail of genes used to regenerate cells could one day be replaced with small drug-like molecules that would offer safer and easier delivery.

We've now laid a solid foundation for developing a way to reverse the damage [done by a heart attack] something previously thought impossible and changing the way that doctors may treat heart attacks in the future, said Dr Deepak Srivastava, director of cardiovascular disease at the Gladstone Institutes. Our findings here serve as a proof of concept that human fibroblasts can be re-programmed successfully into beating heart cells.

In 2012, Dr Srivastava and his team reported in the journal Nature that, by injecting three genes into the hearts of live mice that had been damaged by heart attack, fibroblasts could be turned into working heart cells.

The scientists attempted the same technique using human fibroblasts from foetal heart cells, embryonic stem cells and neonatal skin cells, injected with genes in petri dishes in the lab. An increased number of genes was required to transform the human cells, and the efficiency of the transformed cells was low, but the team were encouraged by the results.

While almost all the cells in our study exhibited at least a partial transformation, about 20 per cent of them were capable of transmitting electrical signals a key feature of beating hearts, said Gladstone staff scientist Ji-dong Fu, the studys lead author.

The number of people who survive heart attacks has increased considerably in recent decades. The British Heart Foundation (BHF) said earlier this year that 70 per cent of women and 68 per cent of men were now surviving. However, success in keeping people alive after a heart attack has led to a rise in the number of people suffering from the long-term after-effects, which include debilitating heart failure.

Read more here:
Scientists come closer to 'mending broken hearts' by using gene therapy to repair muscles damaged in heart attacks

Recommendation and review posted by Bethany Smith

Stem cell therapy treats animal ailments, vets see improvement
Stem cell therapy is typically tied to controversy but now, some Southern Arizona veterinarians are turning to a different form of the cutting edge treatment...

By: kgun9

View post:
Stem cell therapy treats animal ailments, vets see improvement - Video

Recommendation and review posted by simmons

Targeting Cancer with Genetically Engineered Poliovirus
PVS-RIPO is a genetically engineered poliovirus that is being investigated as a new anti-cancer agent at the Preston Robert Tisch Brain Tumor Center at Duke....

By: Duke Media Services - Duke University

See more here:
Targeting Cancer with Genetically Engineered Poliovirus - Video

Recommendation and review posted by Bethany Smith